Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Vemurafenib Has Durable Activity in NSCLC Harboring BRAF V600 Mutations

Publish date:: July 23, 2019

Key clinical point: Vemurafenib has durable antitumor activity in patients with BRAF V600–mutant NSCLC.

Major finding: The objective response rate was 37.1% overall (37.5% in previously untreated patients and 37.0% in previously treated patients).

Study details: Phase 2 open-label, single-arm, multicohort trial with analysis of 62 patients having BRAF V600–mutant NSCLC (VE-BASKET trial).

Disclosures: Dr. Subbiah disclosed having a consulting or advisory role with or receiving research funding from numerous pharmaceutical companies. The study was sponsored by Hoffmann–La Roche.

Citation:

Subbiah V et al. JCO Precis Oncol. 2019 June 27. doi: 10.1200/PO.18.00266.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Lung Cancer

Two different radiation boost strategies reduce local failures in NSCLC,

Rechallenge ‘reasonable’ for some with small-cell lung cancer,

Black patients with ES-SCLC get less chemo but have better survival,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Reduced cancer mortality with Medicaid expansion,